29786-43-4

Usage

Uses

Used in Pharmaceutical Industry:
1-(3-(TrifluoroMethyl)phenyl)cyclobutanecarbonitrile is utilized as a building block for the synthesis of various biologically active molecules. Its unique structure and properties make it a valuable component in the development of new drugs and materials.
Used in Organic Synthesis:
In the realm of organic synthesis, 1-(3-(TrifluoroMethyl)phenyl)cyclobutanecarbonitrile serves as a key intermediate, facilitating the creation of complex organic compounds through its reactivity and structural features.
Used in Chemical Research:
1-(3-(TrifluoroMethyl)phenyl)cyclobutanecarbonitrile is employed in chemical research to explore its potential applications and to understand its chemical behavior, which can contribute to the advancement of scientific knowledge and the discovery of new chemical processes.

Upstream product

• 109-64-8 1,3-dibromo-propane 
• 2338-76-3 3-trifluoromethylphenylacetonitrile 

Downstream Products

• 29786-53-6 1-(3-(trifluoromethyl)phenyl)cyclobutane-1-carboxamide 
• 1032464-46-2 C₁₃H₁₂F₃N₃S 
• 1432492-72-2 tert-butyl 2-(hydroxy(1-(3-(trifluoromethyl)phenyl)cyclobutyl)methyl)-pyridin-3-ylcarbamate 
• 1432048-60-6 (3-aminopyridin-2-yl){1-[3-(trifluoromethyl)phenyl]cyclobutyl}methanol 
• 1432492-71-1 1-(3-(trifluoromethyl)phenyl)cyclobutanecarbaldehyde 
• 151157-58-3 1-(3-trifluoromethylphenyl)cyclobutane carboxylic acid 
• 29786-33-2 (<1-(α,α,α-Trifluoro-m-tolyl)cyclobutyl>carbonyl)carbamsaeureethylester 
• 29973-63-5 (<1-(α,α,α-Trifluoro-m-tolyl)cyclobutyl>carbonyl)carbamsaeuremethylester 
• 29770-39-6 (<1-(α,α,α-Trifluor-m-tolyl)-cyclobutyl>-carbonyl)-harnstoff 
• 29770-26-1 <1-(α,α,α-Trifluor-m-tolyl)-cyclobutyl>-carbonylisocyanat 

Relevant academic research and scientific papers

Synthesis method of arylcyclobutane compound

The present invention discloses a method for synthesizing an arylcyclobutane compound to 1eq phenylacetonitrile and 1.1eq 1-bromo-3-chloropropane as raw material, N,N- dimethylacetamide as a solvent, plus 2.5eq sodium hydride, under the protection of iner

Oxadiazole Amine Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same

The present invention relates to a novel compound having an activity of inhibiting histone deacetylase 6 (HDAC6), an optical isomer thereof or a pharmaceutically acceptable salt thereof, a use thereof for preparation of a drug for treatment, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing the same. The novel compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof according to the present invention has an activity of inhibiting histone deacetylase 6 (HDAC6), and is effective for preventing or treating HDAC6-related diseases, including infectious diseases; neoplasm; endocrine, nutritional and metabolic diseases; mental and behavior disorders; nerve disorders; eye and adnexa diseases; cardiovascular diseases; respiratory diseases; digestive organ diseases; skin and subcutaneous tissue diseases; musculoskeletal and connective tissue diseases; or congenital malformation, deformation and chromosomal abnormality.COPYRIGHT KIPO 2017

Identification of A Novel Small-Molecule Binding Site of the Fat Mass and Obesity Associated Protein (FTO)

N-(5-Chloro-2,4-dihydroxyphenyl)-1-phenylcyclobutanecarboxamide (N-CDPCB, 1a) is found to be an inhibitor of the fat mass and obesity associated protein (FTO). The crystal structure of human FTO with 1a reveals a novel binding site for the FTO inhibitor and defines the molecular basis for recognition by FTO of the inhibitor. The identification of the new binding site offers new opportunities for further development of selective and potent inhibitors of FTO, which is expected to provide information concerning novel therapeutic targets for treatment of obesity or obesity-associated diseases.

NOVEL TRPV3 MODULATORS

Disclosed herein are modulators of TRPV3 of formula (II): wherein G1, X1, X2, X3, X4, X5, G2, Ra, Rb, and u are as defined in the specification. Composition

NOVEL TRPV3 MODULATORS

Disclosed herein are modulators of TRPV3 of formula (II): wherein G1, X1, X2, X3, X4, X5, G2, Ra, Rb, and u are as defined in the specification. Composition

NOVEL TRPV3 MODULATORS

Disclosed herein are modulators of TRPV3 of formula (I) wherein G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

NOVEL TRPV3 MODULATORS

Disclosed herein are modulators of TRPV3 of formula (I), wherein G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, and p are as defined in the specifica